Munich, Germany, 16 September 2016 - Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly reduced the risk of the primary composite endpoint of time to first occurrence of either cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 26% vs placebo, when added to standard of care in 3,297 adults with type 2 diabetes at high CV risk. 1 These results were based on an accumulation of first major adverse CV events (MACE) in 254 people. 1
The main results from SUSTAIN 6 were presented today at the 52 nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2016 2 and also published in the New England Journal of Medicine . 1
|Katrine Sperling||+45 4442 firstname.lastname@example.org|
|Åsa Josefsson||+45 3079 email@example.com|
|Peter Hugreffe Ankersen||+45 3075 firstname.lastname@example.org|
|Melanie Raouzeos||+45 3075 email@example.com|
|Hanna Ögren||+45 3079 firstname.lastname@example.org|
|Kasper Veje (US)||+1 609 235 email@example.com|
Last updated on: 17/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.